What is Zacks Research’s Forecast for Pfizer Q1 Earnings?

Pfizer Inc. (NYSE:PFE) – Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Pfizer in a research note issued on Monday, February 24th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $0.63 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.82 EPS, Q1 2026 earnings at $0.63 EPS and Q2 2026 earnings at $0.58 EPS.

Other research analysts also recently issued reports about the company. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Down 1.3 %

Shares of NYSE:PFE opened at $26.09 on Thursday. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a market capitalization of $147.83 billion, a PE ratio of 18.50, a PEG ratio of 0.64 and a beta of 0.64. The business has a 50 day moving average of $26.35 and a two-hundred day moving average of $27.35. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Norges Bank purchased a new position in Pfizer during the fourth quarter worth $2,328,986,000. Charles Schwab Investment Management Inc. grew its position in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Starboard Value LP purchased a new stake in Pfizer during the fourth quarter valued at about $407,730,000. Raymond James Financial Inc. purchased a new stake in Pfizer during the fourth quarter valued at about $274,694,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.